Gene · 974
Papers4,161
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
681 to 700 of 4,161
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The Evolution of Therapies Targeting Bruton Tyrosine Kinase for the Treatment of Chronic Lymphocytic Leukaemia: Future Perspectives. | Cancers (Basel) | 2023 | 37174062 | PubTator, text mining | PubMed |
RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. | Ann Hematol | 2023 | 37171597 | PubTator, text mining | PubMed |
| High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. | Blood Adv | 2023 | 37171397 | PubTator, text mining | PubMed |
| Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles. | Front Neurol | 2023 | 37168665 | PubTator, text mining | PubMed |
| Protocol for using single-cell sequencing to study the heterogeneity of NF1 nerve sheath tumors from clinical biospecimens. | STAR Protoc | 2023 | 37167059 | PubTator, text mining | PubMed |
| Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. | Exp Hematol Oncol | 2023 | 37158921 | PubTator, text mining | PubMed |
| Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer. | Cancer Commun (Lond) | 2023 | 37158690 | PubTator, text mining | PubMed |
| Potential Biomarkers for Parkinson Disease from Functional Enrichment and Bioinformatic Analysis of Global Gene Expression Patterns of Blood and Substantia Nigra Tissues. | Bioinform Biol Insights | 2023 | 37153842 | PubTator, text mining | PubMed |
| Liquid biopsy in hematological malignancies: current and future applications. | Front Oncol | 2023 | 37152045 | PubTator, text mining | PubMed |
| DISC1 as a prognostic biomarker correlated with immune infiltrates in gastric cancer. | Heliyon | 2023 | 37151698 | PubTator, text mining | PubMed |
| Case report: Circulating tumor DNA technology displays temporal and spatial heterogeneity in Waldenström macroglobulinemia during treatment with BTK inhibitors. | Pathol Oncol Res | 2023 | 37151353 | PubTator, text mining | PubMed |
| Identification and validation of immunogenic cell death-related score in uveal melanoma to improve prediction of prognosis and response to immunotherapy. | Aging (Albany NY) | 2023 | 37142279 | PubTator, text mining | PubMed |
| Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas. | Cancer Discov | 2023 | 37141112 | PubTator, text mining | PubMed |
| The potential crosstalk between tumor and plasma cells and its association with clinical outcome and immunotherapy response in bladder cancer. | J Transl Med | 2023 | 37138324 | PubTator, text mining | PubMed |
| The immunopeptidome landscape associated with T cell infiltration, inflammation and immune editing in lung cancer. | Nat Cancer | 2023 | 37127787 | PubTator, text mining | PubMed |
| Integration of molecular testing for the personalized management of patients with diffuse large B-cell lymphoma and follicular lymphoma. | World J Clin Oncol | 2023 | 37124135 | PubTator, text mining | PubMed |
| Unusual Instance of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma Confined to a Colonic Polyp. | Cureus | 2023 | 37123738 | PubTator, text mining | PubMed |
| Pleurisy as a Sign of Chronic Lymphocytic Leukemia. | Cureus | 2023 | 37123706 | PubTator, text mining | PubMed |
| Latent disease similarities and therapeutic repurposing possibilities uncovered by multi-modal generative topic modeling of human diseases. | Bioinform Adv | 2023 | 37123453 | PubTator, text mining | PubMed |
| Multi-targeted immunotherapeutics to treat B cell malignancies. | J Control Release | 2023 | 37121515 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/974/papers?page=35